Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma
Jared Silver,Andrea Steffens,Benjamin Chastek,Arijita Deb
DOI: https://doi.org/10.2147/jaa.s444693
2024-03-24
Journal of Asthma and Allergy
Abstract:Jared Silver, 1 Andrea Steffens, 2 Benjamin Chastek, 2 Arijita Deb 3 1 Medical Affairs, GSK, Durham, NC, USA; 2 Optum, Eden Prairie, MN, USA; 3 Value, Evidence and Outcomes, GSK, Upper Providence, PA, USA Correspondence: Arijita Deb, Value, Evidence and Outcomes, GSK, 1250 S Collegeville Road, Upper Providence, PA, 19426, USA, Tel +1 267 377-5717, Email Purpose: Real-world data on mepolizumab in patients with severe asthma and allergic and non-allergic phenotypes are limited. This study investigated the effectiveness of mepolizumab treatment in patients with severe asthma with allergic and non-allergic phenotypes. Patients and Methods: This retrospective cohort study (GSK ID: 214148) used administrative claims data from the Optum Research Database. Eligible patients were ≥ 6 years of age with asthma and had ≥ 2 mepolizumab claims post-index. Index date was the first mepolizumab claim/administration (January 2016–December 2018). Patients were divided into two cohorts: allergic and non-allergic asthma, based on diagnosis codes, medication use and lab test results. Outcomes included the rate of asthma-related exacerbations and oral corticosteroid (OCS) use during the 12 months before (baseline period) and 12 months after (follow-up period) mepolizumab initiation. Study ended in December 2019. Results: Overall, 240 (44.6%) and 298 (55.4%) patients were included in the allergic and non-allergic asthma cohorts, respectively. Mean (standard deviation [SD]) counts of asthma-related exacerbations were significantly reduced from baseline to follow-up in both the allergic and non-allergic asthma cohorts (3.2 [2.5] to 2.1 [2.1], p < 0.001 and 2.5 [2.2] to 1.7 [1.9], p < 0.001, respectively). The mean number of OCS pharmacy claims was significantly decreased by 33.3% and 41.4% from baseline to follow-up in the allergic and non-allergic cohorts, respectively (p < 0.001); mean daily OCS dose significantly decreased by 30.6% and 45.4%, respectively (p < 0.001) as well as the mean number of OCS bursts, which decreased by 44.9% and 41.8%, respectively (p < 0.001). No significant differences were observed between cohorts in reductions in asthma exacerbations, counts of OCS pharmacy claims or OCS bursts (baseline to follow-up). Conclusion: Mepolizumab significantly reduced asthma exacerbations and OCS use in patients with allergic and non-allergic asthma, suggesting that mepolizumab provides real-world benefit in severe asthma irrespective of whether a patient has an allergic phenotype. Keywords: severe asthma, phenotype, exacerbation, oral corticosteroid Severe asthma is characterized by treatment with high-dose inhaled corticosteroids (ICS) in addition to a second controller and/or systemic corticosteroids (SCS), including oral corticosteroids (OCS). 1 However, symptoms may remain uncontrolled leading to frequent asthma exacerbations requiring short-acting ß 2 -agonist (SABA) and OCS use, emergency treatment, or hospitalization. 1,2 Severe asthma can be classified by phenotype including those with elevated sputum and/or blood eosinophil counts (severe asthma with an eosinophilic phenotype) or sensitivity to environmental allergens plus elevated immunoglobulin E (IgE) levels (severe allergic asthma). 3–5 These phenotypes share features including being mechanistically driven by type 2 inflammation and the presence of elevated eosinophil counts. 5 Approximately three-quarters of patients with severe asthma with an eosinophilic phenotype also have an allergic phenotype. 6 Treatments targeting the common mechanisms underlying phenotypes, such as elevated eosinophil counts, plausibly provide benefit across asthma phenotypes. 5 Mepolizumab is a humanized monoclonal antibody approved in Europe and the USA as an add-on therapy for the treatment of severe asthma. 7,8 By specifically targeting interleukin (IL)-5, a cytokine that promotes differentiation, activation, and eosinophil survival, mepolizumab enables a precision medicine approach to eosinophilic disease. 9–11 Mepolizumab efficacy in patients with severe asthma is well documented in clinical trials, 12–14 post hoc analyses of clinical trials, 15,16 and real-world studies. 17–20 However, most data on mepolizumab efficacy in patients with and without allergic phenotypes is limited to clinical studies. Post hoc analyses of the DREAM (NCT01000506), MENSA (NCT01691521), and MUSCA (NCT02281318) clinical trials demonstrated similar clinical benefit of mepolizumab in patients with severe asthma irrespective of atopic status, prior omalizumab use, IgE level and sensitivity to particular allergens.<s -Abstract Truncated-
immunology,allergy,respiratory system